BIP Asia 2011

2011年12月2日

Dr. Jacqueline C. Lui, Managing Director of Eagle IP Limited, gave a talk on “Why Patent Protection is Required for all Competitive Technologies and Innovations: in China and Worldwide” during the BIP Asia 2011 at the Hong Kong Convention & Exhibition Centre.

我們過去活動

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

2025年5月21日

Eagle IP is Coming Back to LSPN in Boston!

2025年4月24日

AIPLA Women in IP Global Networking Event in Hong Kong

2025年4月3日

Talk at Hong Kong Christian Service

2024年10月31日

Talk for HKUST Entrepreneurship 101 Training Program

2024年10月31日

IP Training Programme on patent commercialization and technology transfer

2024年10月8日

Recommended Insights

Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

2022年12月13日

There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]

What is the difference between an Invention Patent and a Utility Model Patent?

2021年8月13日

There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]

New Policies to Promote Importation of Innovative Drugs

2018年11月8日

At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日

The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]